Absci Corporation (ABSI)
|Net Income (ttm)||-47.61M|
|Trading Day||July 23|
|Day's Range||21.50 - 24.00|
|52-Week Range||20.88 - 24.00|
VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pr...
It plans to list on the Nasdaq exchange under the ticker symbol ABSI.
Vancouver biotech company AbSci announced its intention to file for an initial public offering on Wednesday.
Absci Corporation has filed to go public with an IPO on the NASDAQ.
Absci was founded with the goal of creating better medicines and helping them reach patients sooner. With our AI-powered Integrated Drug Creation Platform we enable the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. We leverage proprietary synthetic biology technologies and deep learning AI to predict, identify, design, construct, screen, select and scale production of novel biologic drug candidates, and learn from the data we generate. Our goal is to become the partner o... [Read more...]
|IPO Date |
Jul 22, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, Absci's revenue was $4.78 million, an increase of 132.04% compared to the previous year's $2.06 million. Losses were -$14.35 million, 118.0% more than in 2019.